Archives
-
LNP mRNA Bleb Structures Improve Transfection Potency
2026-09-16
The reference study shows that mRNA-rich bleb structures in lipid nanoparticles can be induced by formulation conditions, including high-concentration pH 4 sodium citrate, even when the ionizable lipid is not intrinsically highly active. These structures were associated with improved in vitro and in vivo expression, apparently in part because they preserved encapsulated mRNA integrity rather than simply increasing intracellular delivery.
-
Gasdermin C Drives Stemness and Immune Evasion in PDAC
2026-09-16
A 2024 Advanced Science study identifies GSDMC as a noncanonical regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion. The work links ADAM17-dependent cleavage and nuclear GSDMC activity to CXCL9-mediated immune remodeling, suggesting that blocking this pathway may improve responses to KRASG12D inhibition and PD-1 checkpoint blockade.
-
β-Elemene: From AMPK Insight to Translational Strategy
2026-09-15
A translational framework for using β-Elemene and Levo-β-elemene to connect AMPK-centered adipogenesis findings with apoptosis, inflammation, neuroprotection, and PI3K/AKT/mTOR pathway research.
-
Topotecan: Pharmacology, Mechanism, and Clinical Evidence
2026-09-15
The 1999 review by Kollmannsberger and colleagues established topotecan as a clinically relevant, water-soluble topoisomerase I inhibitor with a distinctive DNA-damaging mechanism. Its analysis connected lactone chemistry, pharmacokinetics, dose-limiting myelosuppression, and early clinical activity in ovarian cancer, small-cell lung cancer, and other malignancies.
-
Danazol: From Steroid Perturbation to Model Validity
2026-09-14
Danazol and Danocrine are valuable endocrine research tools, but their interpretation depends on separating receptor activity, steroidogenesis, and hypothalamic responses. This article examines a 2025 rat study to show how model choice and endpoint selection improve mechanistic assay validity.
-
N3-kethoxal Workflows for RNA and ssDNA Mapping
2026-09-14
N3-kethoxal converts exposed guanines in RNA and single-stranded DNA into stable, clickable chemical records. This guide connects RNA structure probing with KAS-ATAC-style chromatin workflows, emphasizing assay design, controls, optimization, and interpretation.
-
Nifedipine (BAY-a-1040): From Calcium to Translation
2026-09-13
Nifedipine (BAY-a-1040) is more than a calcium channel inhibitor: it is a practical perturbation tool for connecting calcium-dependent biology with translational assay design. This thought-leadership article explains how to validate calcium influx inhibition, interpret exploratory iron and fungal findings, and use PXR-driven liver research as a strategic framework without confusing distinct mechanisms.
-
Predicting siRNA Codelivery with Netarsudil
2026-09-12
Slaughter and colleagues developed a quantitative framework for predicting when ionizable drugs can complex siRNA and function as components of drug-containing nanoparticles. Netarsudil, or AR-13324, was a successful test case: its predicted loading behavior enabled codelivery of CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, where CTGF expression and actin network density were reduced.
-
FGFR–TGFβ/PI3K/AKT Control of Periostin
2026-09-11
Labrèche et al. identify a context-dependent cross talk among FGFR, TGFβ, and PI3K/AKT signaling that regulates periostin expression in HER2-positive breast cancer cells. The study separates stromal periostin production from tumor-cell acquisition of periostin and provides a mechanistic framework for interpreting extracellular-matrix remodeling in aggressive breast cancer.
-
SAPC-LNP mRNA Vaccines and Durable Immune Memory
2026-09-11
The reference study introduces SAPC-LNPs, which combine a sialic acid–lipid derivative with a cleavable PEG–lipid derivative to improve dendritic-cell delivery while reducing immune memory directed against the carrier. In mouse mRNA cancer-vaccine experiments, this design produced efficient endosomal escape, stronger tumor-antigen memory, weaker anti-LNP memory, and more durable protective activity than the comparator formulation.
-
Small-Biopsy Dye Models in Surgical Pathology
2026-09-10
The reference study evaluates whether simple dyes can make 0.2–0.3 cm tissue fragments easier to recognize during routine processing without compromising slide interpretation. It identifies hematoxylin as the most practical marker, while showing that merbromin and Alcian blue can also improve visibility but require greater consideration of toxicity and diagnostic interference.
-
Enzyme-Induced Hypoxia and Urothelial Inflammation
2026-09-10
The reference study shows that hypoxia duration determines whether rat urothelial cells develop a measurable inflammasome-associated response. Short exposure stabilized HIF-1α and increased nitric oxide activity without increasing caspase-1, whereas longer exposure promoted caspase-1 activity that was attenuated by glutathione or verapamil, supporting a ROS-linked TXNIP/NLRP3 mechanism.
-
X-Gal A2539: Reliable β-Galactosidase Assays
2026-09-09
This scenario-based guide explains when X-Gal is appropriate for β-galactosidase reporter assays, blue-white colony screening, and molecular cloning—and when it should not replace a direct viability assay. It also details formulation, solubilization, controls, and vendor-selection considerations for X-Gal SKU A2539.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-09-09
The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, supports detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. This guide focuses on practical assay setup and QC where no directly matched paper evidence is available; the reagent is for research use only and is not validated for diagnostic, medical, or therapeutic applications.
-
DNMT Inhibition Restores Innate Antitumor Immunity
2026-09-08
The reference study shows that DNMT inhibition can reverse epigenetic silencing of cGAS–STING while also increasing cytosolic double-stranded RNA signaling through RIG-I/MDA5–MAVS. These complementary innate immune pathways improved interferon-related antitumor activity and provide a mechanistic basis for combining decitabine with cisplatin or immunotherapy-oriented strategies.